United Therapeutics (UTHR)
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term.
Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Company profile
Ticker
UTHR
Exchange
Website
CEO
Martine Rothblatt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Lung Bioengineering Inc. • Lung Biotechnology PBC, a Delaware public benefit corporation • Revivicor, Inc. • United Therapeutics Europe, Ltd., a company incorporated • Unither Biotech Inc. • Unither Bioelectronics, Inc. • Unither Pharma, LLC • Unither Pharmaceuticals, LLC • Unither Telmed, Ltd. • Unither Therapeutik GmbH ...
IRS number
521984749
UTHR stock data
News

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
4 May 22
Recap: United Therapeutics Q1 Earnings
4 May 22
United Therapeutics Q1 EPS $5.03 Beats $3.34 Estimate, Sales $461.90M Beat $420.02M Estimate
4 May 22
Earnings Scheduled For May 4, 2022
4 May 22
Earnings Outlook For United Therapeutics
3 May 22
Press releases
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
4 May 22
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
29 Apr 22
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
27 Apr 22
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
6 Apr 22
United Therapeutics Corporation to Present at the Oppenheimer 32nd Annual Healthcare Conference
8 Mar 22
Analyst ratings and price targets
Current price
Average target
$220.67
Low target
$203.00
High target
$236.00
JP Morgan
Maintains
$223.00
Wedbush
Maintains
$236.00
Ladenburg Thalmann
Maintains
$203.00
Calendar
4 May 22
17 May 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 813.3M | 813.3M | 813.3M | 813.3M | 813.3M | 813.3M |
Cash burn (monthly) | 27.17M | 1.58M | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 42.24M | 2.46M | n/a | n/a | n/a | n/a |
Cash remaining | 771.06M | 810.84M | n/a | n/a | n/a | n/a |
Runway (months of cash) | 28.4 | 512.1 | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 May 22 | Dwek Raymond | Common Stock | Sale back to company | Dispose D | No | Yes | 186.99 | 2,000 | 373.98K | 0 |
5 May 22 | Dwek Raymond | Common Stock | Option exercise | Acquire M | No | Yes | 48.11 | 2,000 | 96.22K | 2,000 |
5 May 22 | Dwek Raymond | Share Tracking Award Common Stock | Option exercise | Dispose M | No | Yes | 48.11 | 2,000 | 96.22K | 0 |
5 May 22 | Mahon Paul A | Common Stock | Sell | Dispose S | No | Yes | 192.9221 | 700 | 135.05K | 36,397 |
5 May 22 | Mahon Paul A | Common Stock | Sell | Dispose S | No | Yes | 191.7233 | 900 | 172.55K | 37,097 |
5 May 22 | Mahon Paul A | Common Stock | Sell | Dispose S | No | Yes | 190.3573 | 3,100 | 590.11K | 37,997 |
5 May 22 | Mahon Paul A | Common Stock | Sell | Dispose S | No | Yes | 189.3765 | 1,300 | 246.19K | 41,097 |
5 May 22 | Mahon Paul A | Common Stock | Option exercise | Acquire M | No | Yes | 111 | 6,000 | 666K | 42,397 |
5 May 22 | Mahon Paul A | Stock Options Common Stock | Option exercise | Dispose M | No | Yes | 111 | 6,000 | 666K | 34,552 |
28 Apr 22 | Dwek Raymond | Common Stock | Sale back to company | Dispose D | No | Yes | 179.34 | 2,000 | 358.68K | 0 |
Institutional ownership, Q4 2021
93.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 405 |
Opened positions | 54 |
Closed positions | 56 |
Increased positions | 134 |
Reduced positions | 155 |
13F shares | Current |
---|---|
Total value | 9.18B |
Total shares | 42.51M |
Total puts | 86.8K |
Total calls | 183.1K |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 4.24M | $916M |
Vanguard | 4.16M | $899.1M |
Avoro Capital Advisors | 3.04M | $655.8M |
Renaissance Technologies | 2.92M | $630.35M |
FMR | 2.52M | $545.25M |
STT State Street | 1.52M | $327.85M |
BK Bank Of New York Mellon | 1.01M | $219.1M |
Wellington Management | 964.75K | $208.46M |
Geode Capital Management | 760.95K | $164.43M |
Fuller & Thaler Asset Management | 731.39K | $158.04M |
Financial report summary
?Competition
Pfizer • Vivus • Gilead Sciences • Actavis • Mannkind • FibroGen • Elbit Imaging • Arena Pharmaceuticals • Cumberland Pharmaceuticals • InsmedManagement Discussion
- Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
- •The outcome of pending and potential future legal and regulatory actions by the U.S. Food and Drug Administration (FDA) and other regulatory and government enforcement agencies, and the anticipated duration of regulatory exclusivity for our products;
- •The timing and outcome of ongoing litigation, including the lawsuit filed against us by Sandoz, Inc. (Sandoz) and Liquidia PAH, LLC (formerly known as RareGen, LLC) (RareGen); the lawsuit filed against us by MSP Recovery; our patent and trade secret litigation with Liquidia Technologies, Inc. (Liquidia) related to its NDA for Yutrepia, and with ANI Pharmaceuticals, Inc. (ANI) related to its abbreviated new drug application (ANDA) seeking FDA approval to market a generic version of Orenitram; our litigation with MSP Recovery Claims, Series LLC, and related entities; and our litigation with the U.S. Department of Health and Human Services (HHS) and the U.S. Health Resource Services Administration (HRSA) related to the Public Health Service’s 340B drug pricing program (the 340B program);
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Good
|
New words:
Agency, aircraft, arguing, attaching, award, bioprinting, CADD, carbon, Carolina, centralized, Circuit, collateral, conflict, drone, escalation, experimental, explained, factual, feasibility, footprint, fulfill, full, gave, Heart, HSS, immunological, judge, living, magistrate, meaningful, military, moot, neighboring, nitric, North, Omicron, onset, Overnight, oxide, parent, pig, plain, plaintiff, proceed, properly, proximate, punitive, reached, repaid, rest, resumed, Robert, Roscigno, RSU, Russia, School, SOFR, stipulation, strength, suing, survived, synthase, temporary, tentative, theory, Toronto, transcend, UAB, UHeart, UKidney, Ukraine, Unitherian, Yutrepia
Removed:
accessibility, accuracy, afford, amending, applied, ASP, ASU, authority, benchmark, biocompatibility, busy, cassette, chemistry, clarification, CMC, commitment, compelling, concomitant, confident, conform, considerable, consistency, consulting, contracting, cope, daily, diagnostic, distancing, donor, earliest, economy, effected, Emerging, emphysema, England, equipped, Europe, exist, expert, extremely, Facilitation, fact, FASB, feedback, fiscal, free, GAAP, hedging, identifying, immaterial, implantable, institution, issuing, Joint, lessen, LIBOR, measuring, Medtronic, municipality, optional, OreniPro, participant, pertaining, PMA, premarket, preventative, printing, prioritization, rapidly, rating, reclassified, recommended, recruit, redesign, redesigned, RemoLife, remotely, removing, repayment, responding, secondary, select, serve, Simplifying, spending, staffing, stage, standard, SteadyMed, stop, supplement, Task, Topic, training, transition, unit, utilizing, virtual, visibility, voluntary
Financial reports
Current reports
8-K
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
4 May 22
8-K
Other Events
22 Apr 22
8-K
Entry into a Material Definitive Agreement
1 Apr 22
8-K
United Therapeutics Corporation Reports Fourth Quarter
24 Feb 22
8-K
Other Events
17 Jan 22
8-K
Other Events
27 Dec 21
8-K
United Therapeutics Corporation Reports Third Quarter 2021 Financial Results
3 Nov 21
8-K
United Therapeutics Provides an Update on the Progress
18 Oct 21
8-K
Entry into a Material Definitive Agreement
1 Oct 21
8-K
United Therapeutics Corporation Reports Second Quarter 2021 Financial Results
4 Aug 21
Registration and prospectus
S-8
Registration of securities for employees
4 Aug 21
S-8
Registration of securities for employees
29 Jul 20
S-8
Registration of securities for employees
31 Jul 19
S-8
Registration of securities for employees
1 Mar 19
S-8
Registration of securities for employees
28 Jun 18
S-8
Registration of securities for employees
28 Jun 15
S-8
Registration of securities for employees
28 Jul 14
S-8
Registration of securities for employees
29 Apr 13
S-8
Registration of securities for employees
25 Jul 12
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Feb 12
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEFA14A
Additional proxy soliciting materials
10 Sep 21
DEFA14A
Additional proxy soliciting materials
19 Aug 21
DEF 14A
Definitive proxy
19 Aug 21
DEFA14A
Additional proxy soliciting materials
4 Aug 21
PRE 14A
Preliminary proxy
14 Jul 21
DEFA14A
Additional proxy soliciting materials
17 Jun 21
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 21
Other
SD
Conflict minerals disclosure
1 Jun 21
UPLOAD
Letter from SEC
29 Dec 20
CORRESP
Correspondence with SEC
22 Dec 20
UPLOAD
Letter from SEC
14 Dec 20
SD
Conflict minerals disclosure
1 Jun 20
SD
Conflict minerals disclosure
29 May 19
CT ORDER
Confidential treatment order
21 Mar 19
CT ORDER
Confidential treatment order
20 Mar 19
SD
Conflict minerals disclosure
31 May 18
CT ORDER
Confidential treatment order
14 Mar 18
Ownership
4
UNITED THERAPEUTICS / PAUL A MAHON ownership change
6 May 22
4
UNITED THERAPEUTICS / RAYMOND DWEK ownership change
6 May 22
4
UNITED THERAPEUTICS / RAYMOND DWEK ownership change
29 Apr 22
4
UNITED THERAPEUTICS / RAYMOND DWEK ownership change
22 Apr 22
4
UNITED THERAPEUTICS / PAUL A MAHON ownership change
22 Apr 22
4
UNITED THERAPEUTICS / RAYMOND DWEK ownership change
15 Apr 22
4
UNITED THERAPEUTICS / CHRISTOPHER PATUSKY ownership change
8 Apr 22
4
UNITED THERAPEUTICS / PAUL A MAHON ownership change
8 Apr 22
4
UNITED THERAPEUTICS / RAYMOND DWEK ownership change
8 Apr 22
4
UNITED THERAPEUTICS / Tommy G Thompson ownership change
30 Mar 22
Patents
Utility
Compounds and methods for delivery of prostacyclin analogs
5 Apr 22
This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Utility
Genetically Modified Pigs for Xenotransplantation of Vascularized Xenografts and Derivatives Thereof
10 Mar 22
The present invention provides certain donor animals, tissues and cells that are particularly useful for xenotransplantation therapies.
Utility
Treatment of Vasculopathy with Prostacyclin and Mesenchymal Stem Cells
3 Mar 22
Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin.
Utility
Salts of treprostinil
1 Feb 22
Provided are novel treprostinil salts as well as methods for making treprostinil salts.
Utility
Compounds and Methods for Delivery of Prostacyclin Analogs
27 Jan 22
This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing
Transcripts
2022 Q1
Earnings call transcript
4 May 22
2021 Q4
Earnings call transcript
27 Feb 22
2021 Q3
Earnings call transcript
3 Nov 21
2021 Q2
Earnings call transcript
4 Aug 21
2021 Q1
Earnings call transcript
5 May 21
2020 Q4
Earnings call transcript
24 Feb 21
2020 Q3
Earnings call transcript
28 Oct 20
2020 Q2
Earnings call transcript
29 Jul 20
2020 Q1
Earnings call transcript
29 Apr 20
2019 Q4
Earnings call transcript
26 Feb 20
Reddit threads
Daily Discussion Thread - May 4th, 2022
4 May 22
Daily Discussion Thread - May 3rd, 2022
3 May 22
Daily Discussion Thread - May 2nd, 2022
2 May 22
Market open summary - Apr 6
6 Apr 22
Daily Discussion Thread - February 24th, 2022
24 Feb 22
Daily Discussion Thread - February 23rd, 2022
23 Feb 22
Daily Discussion Thread - February 22nd, 2022
22 Feb 22
Daily Discussion Thread - February 21st, 2022
21 Feb 22
Morning Update for Tuesday, 1/11/22
11 Jan 22
ATVI has 11 straight days closing green, I have never seen this in any asset.
28 Dec 21